16,344 Shares in Actuate Therapeutics (NASDAQ:ACTU) Acquired by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV purchased a new position in Actuate Therapeutics (NASDAQ:ACTU) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 16,344 shares of the company’s stock, valued at approximately $130,000.

A number of other large investors also recently added to or reduced their stakes in the business. BIOS Capital Management LP purchased a new position in Actuate Therapeutics in the 4th quarter worth approximately $78,753,000. Voss Capital LP purchased a new position in Actuate Therapeutics in the 4th quarter worth approximately $440,000. Sigma Planning Corp purchased a new position in Actuate Therapeutics in the 4th quarter worth approximately $128,000. Envestnet Asset Management Inc. purchased a new position in Actuate Therapeutics in the 4th quarter worth approximately $83,000. Finally, Freestone Capital Holdings LLC purchased a new position in Actuate Therapeutics in the 4th quarter worth approximately $80,000.

Analyst Ratings Changes

A number of analysts have issued reports on ACTU shares. HC Wainwright started coverage on Actuate Therapeutics in a research note on Monday, March 17th. They issued a “buy” rating and a $20.00 price objective on the stock. Craig Hallum started coverage on Actuate Therapeutics in a research note on Tuesday, April 22nd. They issued a “buy” rating and a $21.00 price objective on the stock.

Actuate Therapeutics Stock Up 8.1%

NASDAQ:ACTU opened at $10.55 on Friday. Actuate Therapeutics has a 1 year low of $5.51 and a 1 year high of $11.73. The stock’s 50 day simple moving average is $8.23 and its two-hundred day simple moving average is $8.28.

Actuate Therapeutics (NASDAQ:ACTU) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06).

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.